Harvard Medical School Researchers to Build Next Generation Discovery and Diagnostics Methods with Lumera’s ProteomicProcessor™ Biosensor
BOTHELL, Wash.--(BUSINESS WIRE)--Lumera Corporation (Nasdaq:LMRA), an emerging leader in the field of nanotechnology, announced that Harvard Medical School researchers are now building next generation discovery and diagnostics methods with Lumera’s ProteomicProcessor™ Biosensor.
“We now have a solid foundation on which to begin our development efforts. Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research.”
During the past year, Lumera has placed four beta units with highly respected, world renowned research organizations to demonstrate and establish new applications that take advantage of the instrument’s unprecedented throughput in a label-free format. Harvard has served as a beta site for Lumera’s biosensor platform, the ProteomicProcessor™, since mid-2006. The Harvard collaboration is focused on integrating their NAPPA (Nucleic Acid Programmable Protein Array) technology, which provides a simple and cost-effective way to generate a protein biochip, with the ProteomicProcessor™ to read and analyze the biochip.
“In the past quarter, we have successfully narrowed the window of processing conditions to produce a ProteomicProcessor™ compatible NAPPA array,” said Dr. Joshua LaBaer, Director of the Harvard Institute of Proteomics. “We now have a solid foundation on which to begin our development efforts. Among our first areas of investigation will be probing a family of 200 kinase proteins for their interaction with and among drug families relevant to cancer research.”
“There is a significant amount of value to the pharmaceutical development market in combining these two technologies,” said Dr. Timothy Londergan, Director of Lumera’s Bioscience Business. “This will ultimately lead to new products that take advantage of NAPPA’s unique capability of producing proteins on demand and the ProteomicProcessor’s unique ability to understand in great detail how the proteins are interacting with each other and with other compounds, like, for example, drug candidates. We are particularly interested in using NAPPA to generate a human protein kinase array, allowing us to address a very large and growing segment of the drug discovery market with a high value consumable product.”
According to Frost and Sullivan, the pharmaceutical industry spends nearly one third of its $50 billion of research and development dollars on kinase inhibitor therapeutics. Kinases are a class of proteins which are known to signal certain illnesses, including some cancers, to the “on” or diseased state. Kinase inhibitors effectively can turn the “on” signal to an “off” state. Interest in this area has been propelled by the success of Gleevec, a multibillion drug from Novartis which was the first approved drug to directly turn off the signal of a protein known to cause a cancer.
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.